Literature DB >> 10649788

Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin.

M D Kohls1, D A Lappi.   

Abstract

Immunotoxins, consisting of antibodies coupled to toxins, are extremely useful tools in the elimination of specific cell populations in vitro and in vivo for research and therapeutic applications. The antibody is used to target the toxin to a specific cell population, which is distinguished by its cell-surface antigen. Not all antibodies are suitable for creating an immunotoxin, and large numbers of antibodies may need to be screened. This is a time-consuming and expensive process if each potential candidate must be conjugated to the toxin and purified. A faster and more economical way to identify potential targeting antibodies is to use a second immunotoxin, an anti-IgG antibody that is coupled to the toxin. The second immunotoxin eliminates the need to couple every candidate antibody to the toxin because it can simply be added to cells in culture with the antibody of interest. Using this method, many antibodies can be screened quickly and efficiently for their ability to internalize.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10649788     DOI: 10.2144/00281pf01

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  13 in total

1.  Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate.

Authors:  Koos E Hovinga; Fumiko Shimizu; Rong Wang; Georgia Panagiotakos; Maartje Van Der Heijden; Hamideh Moayedpardazi; Ana Sofia Correia; Denis Soulet; Tamara Major; Jayanthi Menon; Viviane Tabar
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

2.  Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells.

Authors:  Xiao-Yan Zhao; Hsiao-Lai Liu; Bing Liu; Joerg Willuda; Gerhard Siemeister; Mithra Mahmoudi; Harald Dinter
Journal:  Transl Oncol       Date:  2008-07       Impact factor: 4.243

3.  Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.

Authors:  Yang Feng; Yanping Wang; Zhongyu Zhu; Wei Li; Robyn T Sussman; Michael Randall; Kristopher R Bosse; John M Maris; Dimiter S Dimitrov
Journal:  MAbs       Date:  2016-02-24       Impact factor: 5.857

4.  TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.

Authors:  Devin B Lowe; Camille K Bivens; Alexis S Mobley; Christian E Herrera; Amanda L McCormick; Timea Wichner; Manoj K Sabnani; Laurence M Wood; Jon A Weidanz
Journal:  MAbs       Date:  2017 May/Jun       Impact factor: 5.857

5.  Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity.

Authors:  Ritsuko Sawada; Shu-Man Sun; Xiaohong Wu; Feng Hong; Govind Ragupathi; Philip O Livingston; Wolfgang W Scholz
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

6.  SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas.

Authors:  Nivedita Mitra; Kalyan Banda; Tasha K Altheide; Lana Schaffer; Teresa L Johnson-Pais; Joke Beuten; Robin J Leach; Takashi Angata; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2011-05-09       Impact factor: 5.157

7.  Selective immunolesions of cholinergic neurons in mice: effects on neuroanatomy, neurochemistry, and behavior.

Authors:  J Berger-Sweeney; N A Stearns; S L Murg; L R Floerke-Nashner; D A Lappi; M G Baxter
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

8.  Medullary serotonergic neurones and adjacent neurones that express neurokinin-1 receptors are both involved in chemoreception in vivo.

Authors:  Eugene E Nattie; Aihua Li; George B Richerson; George Richerson; Douglas A Lappi
Journal:  J Physiol       Date:  2004-01-14       Impact factor: 5.182

9.  Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme.

Authors:  Oscar Persson; Leif G Salford; Johan Fransson; Bengt Widegren; Carl A K Borrebaeck; Bo Holmqvist
Journal:  J Neurooncol       Date:  2009-10-07       Impact factor: 4.130

10.  Immunoablation of cells expressing the NG2 chondroitin sulphate proteoglycan.

Authors:  Giampaolo Leoni; Marcus Rattray; Daniel Fulton; Andrea Rivera; Arthur M Butt
Journal:  J Anat       Date:  2013-11-20       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.